Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Data on the safety of selective serotonin-reuptake inhibitors (SSRIs) in pregnancy are inconsistent. We examined associations between SSRI use during early pregnancy and risk of congenital malformations in infants. METHODS: Set in Northern Denmark, our population-based prevalence study included 216,042 women who had a live birth after the 20th week of gestation. We compared the prevalence of malformation in infants born to women who redeemed at least one SSRI prescription during early pregnancy with the prevalence in infants born to women who redeemed no SSRI prescriptions during their pregnancies. Drug use data were extracted from prescription databases, while data on congenital malformations were obtained from the National Registry of Patients. RESULTS: The 2,062 women with SSRI prescriptions during early pregnancy gave birth to 105 (5.1%) infants with malformations, while the 213,712 women with no SSRI prescriptions gave birth to 7,449 (3.5%) infants with malformations. SSRI use was associated with an increased risk of malformations overall (odds ratio [OR] = 1.3; 95% confidence interval (CI): 1.1-1.6) and cardiac malformations (OR = 1.7; 95% CI: 1.1-2.5). For specific SSRIs, we found an increased risk for septal defects associated with sertraline. CONCLUSIONS: We found little overall association between use of SSRIs during pregnancy and congenital malformations, but our findings suggest an association between maternal SSRI use in early pregnancy and cardiac malformations which could be causal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
Alwan, S., Reefhuis, J., Rasmussen, S. A., Olney, R. S., & Friedman, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066584 · Cited by 495 · cited 1×
“Furthermore, maternal SSRI use have been associated with the risk of congenital cardiac malformations in some but not all studies,(11,22) and with the risk of omphalocele, anencephaly, and craniosynostosis.(22) The discrepancies may stem from C lin ic al E pi de m io lo gy d ow nl oa de d fr om h ttp s: //w w w .”
The impact of maternal depression in pregnancy on early child development
Deave, T., Heron, J., Evans, J., & Emond, A. (2008) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01752.x · Cited by 479
Use of antidepressant medications during pregnancy: a multisite study
Andrade, S. E., Raebel, M. A., Brown, J., Lane, K., Livingston, J., Boudreau, D., Rolnick, S. J., Roblin, D., Smith, D. H., Willy, M. E., et al. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.07.036 · Cited by 403
Maternal Depressive Symptoms and the Risk of Poor Pregnancy Outcome
Orr, S. T., & Miller, C. A. (1995) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036172 · Cited by 281
Prevalence and patterns of antidepressant drug use during pregnancy
Ververs, T., Kaasenbrood, H., Visser, G., Schobben, F., de Jong-van den Berg, L., & Egberts, T. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0177-0 · Cited by 174
Bakker, M. K., Kölling, P., Van Den Berg, P. B., De Walle, H. E. K., & De Jong van den Berg, L. T. W. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03048.x · Cited by 158
Cited by
Ross, L. E., Grigoriadis, S., Mamisashvili, L., VonderPorten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.684 · Cited by 268
New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum
Meltzer-Brody, S. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/smbrody · Cited by 266
Reefhuis, J., Devine, O., Friedman, J. M., Louik, C., & Honein, M. A. (2015) · BMJ · doi:10.1136/bmj.h3190 · Cited by 161
Antidepressant use in pregnancy: a critical review focused on risks and controversies
Byatt, N., Deligiannidis, K. M., & Freeman, M. P. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12042 · Cited by 158
“These include hypertrophic stenosis (76), congenital heart defects, and other major abnormalities (41, 65, 73, 77) with fluoxetine, omphalocele (62, 77-79) and cardiac septal defects (62, 77, 79) with sertraline, and omphalocele (62, 77-79), congenital heart defects (62, 77, 79), and neural tube defects (73) with cita…”
BackgroundGao, S.-Y., Wu, Q.-J., Sun, C., Zhang, T.-N., Shen, Z.-Q., Liu, C.-X., Gong, T.-T., Xu, X., Ji, C., Huang, D.-H., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1193-5 · Cited by 152
Metadata
- Authors
- Kornum
- Venue
- Clinical Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 2
- Pages
- 29
- ISSN
- 1179-1349 (ISSN-L)
- OpenAlex
- W2082717009
- Cited by
- 112
- References
- 7
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. https://app.cochat.ai/papers/10.2147/clep.s9256
- The paper
- Kornum. (2010). Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clinical Epidemiology. https://doi.org/10.2147/clep.s9256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.